000 | 01952 a2200553 4500 | ||
---|---|---|---|
005 | 20250515052304.0 | ||
264 | 0 | _c20070515 | |
008 | 200705s 0 0 eng d | ||
022 | _a0946-1965 | ||
024 | 7 |
_a10.5414/cpp44623 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMenarini, M | |
245 | 0 | 0 |
_aTrospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? _h[electronic resource] |
260 |
_bInternational journal of clinical pharmacology and therapeutics _cDec 2006 |
||
300 |
_a623-32 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdministration, Oral |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aBenzilates |
650 | 0 | 4 |
_aConstipation _xchemically induced |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMuscle Hypertonia _xdrug therapy |
650 | 0 | 4 |
_aNortropanes _xadverse effects |
650 | 0 | 4 |
_aParasympatholytics _xadverse effects |
650 | 0 | 4 | _aPatient Compliance |
650 | 0 | 4 | _aPatient Dropouts |
650 | 0 | 4 | _aTablets |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aUrinary Bladder _xdrug effects |
650 | 0 | 4 |
_aUrinary Bladder, Overactive _xdrug therapy |
650 | 0 | 4 |
_aUrinary Incontinence _xdrug therapy |
650 | 0 | 4 |
_aUrodynamics _xdrug effects |
650 | 0 | 4 |
_aVision Disorders _xchemically induced |
700 | 1 | _aDel Popolo, G | |
700 | 1 | _aDi Benedetto, P | |
700 | 1 | _aHaselmann, J | |
700 | 1 | _aBödeker, R H | |
700 | 1 | _aSchwantes, U | |
700 | 1 | _aMadersbacher, H | |
773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 44 _gno. 12 _gp. 623-32 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.5414/cpp44623 _zAvailable from publisher's website |
999 |
_c16757571 _d16757571 |